Jpmorgan Chase & CO F Star Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$4.09 - $6.86 $319 - $535	78 New	78 $0
Q2 2022 Aug 11, 2022	SELL	$2.18 - $6.39 $43,244 - $126,758	-19,837 Reduced 92.98%	1,498 $9,000
Q1 2022 May 11, 2022	BUY	$2.77 - $5.36 $35,708 - $69,095	12,891 Added 152.66%	21,335 $76,000
Q4 2021 Feb 10, 2022	BUY	$4.71 - $7.38 $39,771 - $62,316	8,444 New	8,444 $42,000

44.7K

Ticker FSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,584,700
Description
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck c...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.